AAPS PharmSciTech

, Volume 12, Issue 3, pp 909–916 | Cite as

Solution-Mediated Phase Transformation of Haloperidol Mesylate in the Presence of Sodium Lauryl Sulfate

Research Article

Abstract

Forming a salt is a common way to increase the solubility of a poorly soluble compound. However, the solubility enhancement gained by salt formation may be lost due to solution-mediated phase transformation (SMPT) during dissolution. The SMPT of a salt can occur due to a supersaturated solution near the dissolving surface caused by pH or other solution conditions. In addition to changes in pH, surfactants are also known to affect SMPT. In this study, SMPT of a highly soluble salt, haloperidol mesylate, at pH 7 in the presence of a commonly used surfactant, sodium lauryl sulfate (SLS), was investigated. Dissolution experiments were performed using a flow-through dissolution apparatus with solutions containing various concentrations of SLS. Compacts of haloperidol mesylate were observed during dissolution in the flow-through apparatus using a stereomicroscope. Raman microscopy was used to characterize solids. The dissolution of haloperidol mesylate was significantly influenced by the addition of sodium lauryl sulfate. In conditions where SMPT was expected, the addition of SLS at low concentrations (0.1–0.2 mM) reduced the dissolution of haloperidol mesylate. In solutions containing concentrations of SLS above the critical micelle concentration (CMC) (10–15 mM), the dissolution of haloperidol mesylate increased compared to below the CMC. The solids recovered from solubility experiments of haloperidol mesylate indicated that haloperidol free base precipitated at all concentrations of SLS. Above 5 mM of SLS, Raman microscopy suggested a new form, perhaps the estolate salt. The addition of surfactant in solids that undergo solution-mediated phase transformation can add complexity to the dissolution profiles and conversion.

KEY WORDS

dissolution Raman microscopy salt forms solution-mediated phase transformation surfactant 

Notes

ACKNOWLEDGMENTS

The authors gratefully acknowledge the United States Pharmacopeia for the funding of this project through the USP fellowship 2009–2010. The authors thank Richard Winnike and Manish Gupta for providing haloperidol mesylate for the study.

REFERENCES

  1. 1.
    Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.PubMedCrossRefGoogle Scholar
  2. 2.
    Li S, Wong S, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 2005;22(4):628–35.PubMedCrossRefGoogle Scholar
  3. 3.
    McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res. 2006;23(8):1888–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Cardew PT, Davey RJ. The kinetics of solvent-mediated phase transformations. Proc R Society of London, Series A: Math, Phys and Eng Sci. 1985;398(1815):415–28.CrossRefGoogle Scholar
  6. 6.
    Rodriguez-Hornedo N, Lechuga-Ballesteros D, Wu HJ. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int J Pharm. 1992;85(1–3):149–62.CrossRefGoogle Scholar
  7. 7.
    Rodriguez-Hornedo N, Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci. 1999;88(7):651–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez-Hornedo N, Murphy D. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J Pharm Sci. 2004;93(2):449–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Serajuddin ATM. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews. 2007;59(7):603–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties selection and use. Weinheim: Wiley-VCH; 2002.Google Scholar
  11. 11.
    Greco K, McNamara DP, Bogner R. Solution mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug. J Pharm Sci. 2011. doi: 10.1002/jps.22507. 100(7):2755–2768.
  12. 12.
    Li S, Doyle P, Metz S, Royce AE, Serajuddin ATM. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J Pharm Sci. 2005;94(10):2224–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Jinno J, Oh D-M, Crison JR, Amidon GL. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci. 2000;89(2):268–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Crison JR, Shah VP, Skelly JP, Amidon GL. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J Pharm Sci. 1996;85(9):1005–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res. 2002;19(3):345–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3):413–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen Linna R, Wesley James A, Bhattachar S, Ruiz B, Bahash K, Babu Suresh R. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm Res. 2003;20(5):797–801.PubMedCrossRefGoogle Scholar
  18. 18.
    Mullin JW. Crystallization. 4th ed. Oxford: Butterworth-Heinemann; 2001.Google Scholar
  19. 19.
    Garti N, Zour H. The effect of surfactants on the crystallization and polymorphic transformation of glutamic acid. J Crys Growth. 1997;172(3/4):486–98.CrossRefGoogle Scholar
  20. 20.
    Huang N, Rodriguez-Hornedo N. Effect of micellar solubilization on cocrystal solubility and stability. Cryst Growth Des. 2010;10(5):2050–3.CrossRefGoogle Scholar
  21. 21.
    Greco K, Bergman TL, Bogner R. Design and characterization of a laminar flow-through dissolution apparatus: comparison of hydrodynamic conditions to those of common dissolution techniques. Pharm Dev Technol. 2011;16(1):75–87.PubMedCrossRefGoogle Scholar
  22. 22.
    Fuguet E, Rafols C, Roses M, Bosch E. Critical micelle concentration of surfactants in aqueous buffered and unbuffered systems. Anal Chim Acta. 2005;548(1–2):95–100.CrossRefGoogle Scholar
  23. 23.
    Portar MR. Handbook of surfactants. 2nd ed. Glasgow: Chapman and Hall; 1994.CrossRefGoogle Scholar
  24. 24.
    Jain A, Ran Y, Yalkowsky Samuel H. Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note. AAPS PharmSciTech. 2004;5(3):e45.PubMedCrossRefGoogle Scholar
  25. 25.
    Shlyankevich A, Sanghvi P, Li H, Ebadi M, Ketsela S, Elcsics G, et al. Sodium lauryl sulfate in dissolution media: adverse effects on tablet disintegration and drug release. AAPS PharmSci. 2003;(S1): Abstract 1304.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of PharmacyUniversity of ConnecticutStorrsUSA

Personalised recommendations